CommercialCoverageMedium impact
08.01.32n, Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related Biosimilars
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jun 16, 2025
We identified it
Jun 19, 2026
Summary
Medical necessity criteria and billing codes have been updated for colony-stimulating factor medications including Ryzneuta, Rolvedon, Neulasta and biosimilars. This affects commercial plan coverage and billing requirements for these supportive care medications commonly used in cancer treatment.
Action Required
Before June 16, 2025: Billing team must review and update medical necessity documentation requirements for colony-stimulating factor drugs (Ryzneuta, Rolvedon, Neulasta and biosimilars). Update prior authorization processes and ensure coding compliance with new criteria. Verify billing codes are current in system to prevent claim denials.